Capital Advisors Ltd. LLC Boosts Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Capital Advisors Ltd. LLC boosted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 6.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,435 shares of the biopharmaceutical company’s stock after acquiring an additional 519 shares during the period. Capital Advisors Ltd. LLC’s holdings in Bristol-Myers Squibb were worth $433,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Northern Trust Corp grew its stake in Bristol-Myers Squibb by 5.8% during the third quarter. Northern Trust Corp now owns 25,292,711 shares of the biopharmaceutical company’s stock valued at $1,467,989,000 after acquiring an additional 1,394,158 shares in the last quarter. Invesco Ltd. lifted its position in Bristol-Myers Squibb by 8.6% during the third quarter. Invesco Ltd. now owns 15,606,587 shares of the biopharmaceutical company’s stock valued at $905,806,000 after purchasing an additional 1,240,902 shares during the last quarter. Pacer Advisors Inc. lifted its position in Bristol-Myers Squibb by 48.0% during the fourth quarter. Pacer Advisors Inc. now owns 7,830,948 shares of the biopharmaceutical company’s stock valued at $401,806,000 after purchasing an additional 2,540,360 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Bristol-Myers Squibb by 3.2% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,594,092 shares of the biopharmaceutical company’s stock valued at $287,033,000 after purchasing an additional 172,769 shares during the last quarter. Finally, Pzena Investment Management LLC lifted its position in Bristol-Myers Squibb by 13.8% during the third quarter. Pzena Investment Management LLC now owns 4,924,194 shares of the biopharmaceutical company’s stock valued at $285,800,000 after purchasing an additional 596,625 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Down 8.1 %

Bristol-Myers Squibb stock traded down $3.97 during trading hours on Thursday, hitting $44.89. The stock had a trading volume of 23,108,127 shares, compared to its average volume of 15,608,773. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $90.98 billion, a P/E ratio of 11.70, a price-to-earnings-growth ratio of 1.48 and a beta of 0.39. Bristol-Myers Squibb has a 12-month low of $44.67 and a 12-month high of $69.74. The stock’s 50-day moving average price is $51.22 and its 200-day moving average price is $51.31.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the previous year, the company earned $2.05 earnings per share. Equities research analysts anticipate that Bristol-Myers Squibb will post 6.63 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be paid a $0.60 dividend. The ex-dividend date is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.35%. Bristol-Myers Squibb’s dividend payout ratio is presently 62.18%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on BMY shares. Bank of America lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Wells Fargo & Company boosted their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. Finally, Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $61.18.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.